BioMarin Pharmaceutical Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BMRN Nasdaq 2830 www.biomarin.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioMarin Pharmaceutical Inc.

2 Reasons to Avoid BMRN and 1 Stock to Buy Instead - Jul 17th, 2026 9:45 am
Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside - Jul 16th, 2026 7:06 am
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo - Jul 14th, 2026 8:42 am
BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation - Jul 13th, 2026 4:16 pm
1 of Wall Street’s Favorite Stocks with Competitive Advantages and 2 We Avoid - Jul 13th, 2026 11:10 am
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia - Jul 13th, 2026 7:05 am
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act? - Jul 10th, 2026 6:14 am
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside - Jul 8th, 2026 6:48 am
2 Cash-Heavy Stocks with Exciting Potential and 1 We Ignore - Jun 29th, 2026 5:46 am
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off - Jun 26th, 2026 8:48 am
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest - Jun 25th, 2026 9:37 am
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains? - Jun 25th, 2026 6:45 am
BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment - Jun 23rd, 2026 12:55 pm
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 - Jun 16th, 2026 7:05 am
2 Profitable Stocks Worth Your Attention and 1 We Find Risky - Jun 11th, 2026 3:05 am
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years - Jun 8th, 2026 4:47 am
BioMarin’s VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story - Jun 5th, 2026 12:08 am
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue? - Jun 3rd, 2026 9:30 am
Centene, Deckers and 14 Other ‘Dividend Hopefuls’ - Jun 1st, 2026 11:30 pm
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year - May 30th, 2026 11:56 am